Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$565.14 – $755.96
59% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.54B | $5.92B | $4.51B | $5.41B | $6.22B | $6.72B | $6.57B | $6.53B |
| Cost of revenue | $3.45B | $3.67B | $2.66B | $3.30B | $3.79B | $4.77B | $4.41B | $4.22B |
| Gross profit | $2.09B | $2.25B | $1.85B | $2.11B | $2.44B | $1.95B | $2.16B | $2.31B |
| Gross margin | 37.8% | 38.1% | 41.0% | 39.0% | 39.2% | 29.0% | 32.9% | 35.4% |
| R&D | $110.0M | $123.0M | $84.0M | $185.0M | $95.0M | $105.0M | $0 | $0 |
| Operating income | $842.0M | $972.0M | $901.0M | $851.0M | $1.54B | $880.0M | $964.0M | $1.24B |
| EBITDA | $1.43B | $1.34B | $1.42B | $1.36B | $2.11B | $1.91B | $1.54B | $1.31B |
| Net income | $559.0M | $645.0M | $869.0M | $2.94B | $1.22B | $654.0M | $636.0M | $949.0M |
| Net margin | 10.1% | 10.9% | 19.3% | 54.4% | 19.5% | 9.7% | 9.7% | 14.5% |
| EPS (diluted) | 7.48 | 10.14 | 11.63 | 39.52 | 16.34 | 8.88 | 8.92 | 13.51 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7.0B | $17.46 | $16.93–$18.07 | 1 |
| 2027 | $7.8B | $20.82 | $20.19–$21.55 | 1 |
| 2028 | $8.7B | $24.42 | $23.68–$25.28 | 1 |
| 2029 | $9.8B | $28.62 | $27.75–$29.63 | 1 |
Forward consensus · source: Financial Modeling Prep
LONZA GROUP AG
No one on the platform currently holds LZAGF.
No tracked institution reports a position in LZAGF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-13 | $2.5000 | 2026-05-15 |
| 2026-05-13 | $2.5000 | 2026-05-15 |
| 2025-05-14 | $2.0000 | 2025-05-15 |
| 2025-05-14 | $2.0000 | 2025-05-15 |
| 2024-05-13 | $2.0000 | 2024-05-15 |
No one on the platform has traded LZAGF yet.
| $40.6B |
| — |
| HOCPFHOYA Corporation | $168.50 | -2.80% | $56.4B | — |
| IPSEYIpsen S.A. | $46.50 | +0.00% | $61.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 26.9× earnings vs its 50.0× historical median P/E.
Fair value ≈ $1261 · price $678.51 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$SANA $ELDN $LCTX $LZAGF Medical University initiative aims to integrate 3-liter bioreactors into a closed-loop GMP manufacturing unit to provide personalized, automated cell therapies for Type 1 Diabetes. The industry needs to overcome this problem, good to see progress. https://www.youtube.com/watch?v=LLTadaoFci0
View on StockTwits ↗@Arb_raccoon I can see a hostile bid at $2. A tender offer could happen at any time, simply because the cash and debt position 😉 are too difficult to ignore. I also can see $TMO or $LZAGF or even $DHR making a bid without it making a dent in their share price. Anyone buying this out at $3.X or less is "stealing" it, in my opinion.
View on StockTwits ↗$MXCT So this appears to be trading around below anticipated 2028 cash on hand. The EV is considerably negative, and the company theoretically has enough cash to buy back all outstanding shares (assuming doing so wouldn't begin running up the price). We are down around 30% in a month, with the share price setting new all-time lows. Management is silent. The company appears to be more valuable in a liquidation than it does if they continue operating. Perhaps a take-private option should be considered, given that they have completely failed as a public company thus far. Book value appears to be around the 1.70s... I could see $TMO $DHR or maybe $LZAGF absorbing them for around 2-3 per share without even feeling the expense. Otherwise, we need some exellent news from management asap.
View on StockTwits ↗$CDXS $LZAGF $PFIZER.NSE They do have a preexisting relationship. https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-2006-greener-reaction-conditions-award
View on StockTwits ↗$ILMN $LZAGF Illumina enters licensing agreement with Lonza Synaffix B.V., a Lonza (LZAGY) company, announced it has entered into a licensing agreement with Illumina (ILMN). The agreement grants Illumina access to Synaffix's patented metal-free click chemistry technology. Synaffix's patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing products.
View on StockTwits ↗$NRSN PARTNERS WITH $LZAGF 45 BILLION COMPANY to CURE ALS!! #CureALS $VKTX 10X BANGER $AXSM 10X plus BANGER $CVNA 12X BANGER $NRSN is NEXT you MOFO's
View on StockTwits ↗$LZAGF HUGE ALS PARTNERSHIP WITH $NRSN #CureALS $NRSN presenting POSITVE DATA SOON!! Gave you MOFO's $VKTX at $8.00 (10X BANGER) $AXSM was 10X PLUS BANGER $NRSN LOAD ZONE HERE
View on StockTwits ↗$LZAGF adding around 428 CHF 14% down is way to much for CEO Change
View on StockTwits ↗$LZAGF added massive LONZA Call Warrants Dez 2024
View on StockTwits ↗$LZAGF is rated a Sell since July 21, 2023 and is 38% below its median level.
View on StockTwits ↗$LZAGF High Tide Reports Third Consecutive Quarter of Record Revenue and Adjusted EBITDA of $118.1 Million and $6.6 Million, Respectively! HITI (ASK @ 1.35) HITI.VN (ASK @ 1.75) 13th Straight Quarter of Positive Adjusted EBITDA, Representing a 174% Increase Year-Over-Year and 20% Sequentially, Driven by Significant Cost Reductions in General and Administrative Expenses High Tide Reaches 9.5% of Canadian Cannabis Retail Market Share Outside of Quebec1, Up From 9% in the Previous Quarter PR here : https://finance.yahoo.com/news/high-tide-reports-third-consecutive-200100953.html
View on StockTwits ↗$LZAGF - Hold Lonza and IDEXX Laboratories ( $IDXX ) in the same portfolio. https://www.macroaxis.com/invest/pair-correlation/LZAGF/IDXX/Lonza-vs-IDEXX #portfolio_prospective #better_portfolio #diversify
View on StockTwits ↗$LZAGF Impressive! : Cannara Biotech Inc. Reports Record Q4 and 2022 Fiscal Year Financial Results LOVFF (ASK @ 0.0795) LOVE.VN (ASK @ 0.10) PR is long to read but wow!! (And still under the radar!) Company recorded a record high of $12 million in quarterly revenue (84% YoY increase) and Net Income of $2.6 million! Full year revenues were $36 million, a 108% increase! Delivered its sixth consecutive quarter of positive Adjusted EBITDA of $2.5M, and $5.3M for fiscal year 2022. .lzagf
View on StockTwits ↗@ColdmanSachs $LZAGF $38bn market cap I believe we could be on the verge of a multi adoption from Lonza and Sanofi.
View on StockTwits ↗$LZAGF CNVCF (ASK @ 0.30) BHSC.CN (ASK @ 0.365) Bioharvest Sciences Inc. Successfully Completes Cannabis R&D Program : First company ever to announce that it could produce Cannabis biomass without growing the plant itself! Bioharvest has now produced Cannabis in large scale industrial bioreactors, marking the start of the transition to commercial scale manufacturing. More in PRelease! .t
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.